Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from ASCO

‘Enormous potential’: weight-loss drugs cut cancer risk by a fifth, research shows

Experts believe injections such as Wegovy could play a big role in preventing and treating the disease

The Guardian - UK

Cancer rates among under-50s in UK have risen 24% since 1995, figures show

Increase sharper than in any age group and is likely to be linked to soaring obesity levels, junk food and inactivity, say experts

The Guardian - UK

FDA approves first-of-its-kind new ‘bubble’ treatment for liver cancer

Histotripsy could cause less harmful side effects compared to radiation and chemotherapy, experts say

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA proposes ban on certain hair products that have been tied to cancer

FDA officials could ban the products as soon as next spring

The Independent UK

Man in hospital after Peterhead silo explosion

Incident happened at the ASCO supply base in the South Bay area of the town

Insider UK

Man rushed to hospital after Peterhead supply base explosion involving chemicals

Emergency services rushed to the Asco facility at Harbourside in the town at around 11am on Wednesday, June 21.

Daily Record

Explosion rocks supply base in Peterhead sparking emergency response

Workers are said to have been evacuated from the Asco facility at the Harbourside area of the town.

Daily Record

Read news from The Economist, FT, and more,
with one subscription

New trials show increased survival rates for a range of cancers

A roundup of some of the most promising announcements at a meeting of the American Society of Clinical Oncology.

Al Jazeera

Global ‘silver tsunami’ of older cancer patients is coming, experts warn

Oncologists sound alarm over risk of healthcare systems buckling due to rising need for specific care

The Guardian - UK

Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds

Therapy slows multiple myeloma in patients who have stopped responding to other treatments, say researchers

The Guardian - UK

Bowel cancer patients could be spared radiotherapy, US study suggests

Doctors found some patients could rely on chemotherapy and surgery alone to treat the disease

The Guardian - UK

Breast cancer drug cuts risk of most common form returning by 25%

Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly

The Guardian - UK

Arcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug Class

Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

Investors Business Daily

Brokerages announce downbeat outlook

The total value of securities traded on the Stock Exchange of Thailand is expected to decrease this year from 2022 as concerns about the global economic slowdown and US interest rate hikes affect investor confidence, says the Association of Securities Companies (Asco).

Bangkok Post

Get all your
news in one place.

100’s of premium titles.
One news app.

Bangkok Post

SEC urged to rejig rules after MORE scandal

The Association of Securities Companies (Asco) and its members have proposed the Securities and Exchange Commission (SEC) adjust the regulations regarding stock manipulation in the aftermath of the More Return Plc (MORE) scandal.

Benzinga

Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca plc (NASDAQ:AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ:MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs. Evercore and Citigroup are said to be involved as advisers." Mereo's lead…

Benzinga

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm

With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ:VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens. With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a…

People

Pakorn Peetathawatchai

31 stories

Charles Swanton

25 stories

Ruenvadee Suwanmongkol

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Securities and Exchange Commission

the Stock Exchange of Thailand

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.